[go: up one dir, main page]

NZ336971A - 5-Aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones useful as dopamine agonists - Google Patents

5-Aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones useful as dopamine agonists

Info

Publication number
NZ336971A
NZ336971A NZ336971A NZ33697198A NZ336971A NZ 336971 A NZ336971 A NZ 336971A NZ 336971 A NZ336971 A NZ 336971A NZ 33697198 A NZ33697198 A NZ 33697198A NZ 336971 A NZ336971 A NZ 336971A
Authority
NZ
New Zealand
Prior art keywords
dihydroquinoxaline
aminoalkoxy
dopamine agonists
useful
tetrahydroquinolin
Prior art date
Application number
NZ336971A
Inventor
James Albert Nelson
Uresh Shantilal Shah
Richard Eric Mewshaw
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of NZ336971A publication Critical patent/NZ336971A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The quinoxaline 2,3-dione compound or a pharmaceutically acceptable salt thereof has the formula I wherein: R1 and R2 are independently H, alkyl or -(CH2)mAr or together with the nitrogen atom R1 and R2 form a 1,2,3,4-tetrahydroquinolin-1-yl or 1,2,3,4-tetrahydroquinolin-2-yl; Ar is optionally substituted phenyl, naphthyl or thienyl; m is 1 to 5; n is 1 or 2; Y is H, halo, alkyl or alkoxy. A pharmaceutical composition thereof is useful for treating diseases that respond to treatment with dopamine D2 agonists.
NZ336971A 1997-02-18 1998-01-13 5-Aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones useful as dopamine agonists NZ336971A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80132497A 1997-02-18 1997-02-18
PCT/US1998/001170 WO1998035948A1 (en) 1997-02-18 1998-01-13 5-aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones being dopamine agonists

Publications (1)

Publication Number Publication Date
NZ336971A true NZ336971A (en) 2000-10-27

Family

ID=25180799

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ336971A NZ336971A (en) 1997-02-18 1998-01-13 5-Aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones useful as dopamine agonists

Country Status (14)

Country Link
EP (1) EP0963372A1 (en)
JP (1) JP2001511805A (en)
KR (1) KR20000071162A (en)
CN (1) CN1248249A (en)
AR (1) AR011669A1 (en)
AU (1) AU722616B2 (en)
BR (1) BR9807230A (en)
CA (1) CA2278757A1 (en)
HU (1) HUP0001311A3 (en)
IL (1) IL131160A0 (en)
NZ (1) NZ336971A (en)
TW (1) TW434230B (en)
WO (1) WO1998035948A1 (en)
ZA (1) ZA981306B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2285786E (en) 2008-06-16 2014-01-07 Merck Patent Gmbh Quinoxalinedione derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179551C (en) * 1987-11-10 1996-10-30 Novo Nordisk As Analogous Process for Preparing Therapeutically Effective Quinoxaline Compounds
DK715888D0 (en) * 1988-12-22 1988-12-22 Ferrosan As QUINOXAL COMPOUNDS, THEIR PREPARATION AND USE
US4975430A (en) * 1989-06-16 1990-12-04 The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University CNQX and its analogs as therapeutics for degenerative neural diseases
PT99864B (en) * 1990-12-21 1999-06-30 Schering Ag METHOD FOR PREPARING NEW PHARMACEUTICAL COMPOSITIONS CONTAINING QUISQUALATE RECEPTOR ANTAGONISTS
US5159083A (en) * 1990-12-28 1992-10-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; a class of dopamine receptor subtype specific ligands
ATE404201T1 (en) * 1992-06-22 2008-08-15 Univ California GLYCINE RECEPTOR ANTAGONISTS AND THEIR USE
GB9419318D0 (en) * 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
ATE210657T1 (en) * 1994-10-14 2001-12-15 Merck Patent Gmbh CNS EFFECTIVE (R)-(-)-2-(5-(4-FLUOROPHENYL)-3-PYRIDYLMETHYLAMINOMETHYL)CHROMANE
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists

Also Published As

Publication number Publication date
HUP0001311A3 (en) 2001-07-30
IL131160A0 (en) 2001-01-28
CA2278757A1 (en) 1998-08-20
AU722616B2 (en) 2000-08-10
KR20000071162A (en) 2000-11-25
AR011669A1 (en) 2000-08-30
EP0963372A1 (en) 1999-12-15
JP2001511805A (en) 2001-08-14
BR9807230A (en) 2000-04-25
CN1248249A (en) 2000-03-22
WO1998035948A1 (en) 1998-08-20
TW434230B (en) 2001-05-16
ZA981306B (en) 1999-08-17
HUP0001311A2 (en) 2001-05-28
AU6035098A (en) 1998-09-08

Similar Documents

Publication Publication Date Title
MY135841A (en) Novel benzodioxoles
RO117913B1 (en) Substituted n-((amino-(imino)methyl)phenyl)propyl amide derivatives, pharmaceutical composition containing the same and method of treatment
GB9801690D0 (en) Therapeutic agents
BG106158A (en) New use of compounds as antibacterial agents
PL336164A1 (en) Antimycotic trifluoromethylalkylaminotriazole pyridines
EA200200208A1 (en) SYNERGY COMPOSITION
TR200200579T2 (en) Amino-thyrazolpyridine derivatives.
BR9508057A (en) Compound
JO2311B1 (en) Alkyne-aryl phosphodiesterase-4 inhibitors
FI950309A0 (en) proline amide derivative
NZ514873A (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agents
GB0225475D0 (en) Therapeutic agents
HK1026909A1 (en) Substituted phenyl derivatives, their preparation and use
CY1111951T1 (en) PAINYL-CARBOXAMID COMPOUNDS USEFUL FOR PANTS
GEP20033079B (en) Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency
GEP20074058B (en) 4-(7-halo-2-quino(xa) linyloxy-phenoxy-propionic acid derivatives as antineoplastic agents
ES2178765T3 (en) NEW DERIVATIVES OF 1,7,7-TRIMETHYL-BICYCLE (2.2.1) HEPTANE.
NZ503710A (en) 2-Substituted- 4'-hydroxy-5,9,9-trimethyl-6,7-benzomorphan derivatives useful in treating vascular diseases
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
GEP20063754B (en) Quinoline Derivatives and Use Thereof as Antitumor Agents
CY2225B1 (en) Organic compounds
AU5390900A (en) Potassium channel blocking agents
NZ336971A (en) 5-Aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones useful as dopamine agonists
PL345452A1 (en) Chemotaxis-inhibiting protein of staphylococcus
NO934760L (en) Aryl-substituted heterocyclic compounds